Compare GATX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GATX | RYTM |
|---|---|---|
| Founded | 1898 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.8B |
| IPO Year | 1994 | 2017 |
| Metric | GATX | RYTM |
|---|---|---|
| Price | $178.96 | $106.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $215.50 | $131.14 |
| AVG Volume (30 Days) | 210.6K | ★ 872.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | 17.22 | ★ 28.34 |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $1,740,400,000.00 | N/A |
| Revenue This Year | $42.21 | $55.34 |
| Revenue Next Year | $3.35 | $86.06 |
| P/E Ratio | $75.80 | ★ N/A |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $148.20 | $74.50 |
| 52 Week High | $205.56 | $122.20 |
| Indicator | GATX | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 52.16 |
| Support Level | $166.38 | $98.30 |
| Resistance Level | $183.47 | $113.51 |
| Average True Range (ATR) | 4.86 | 4.15 |
| MACD | 0.24 | -1.46 |
| Stochastic Oscillator | 73.90 | 14.40 |
GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.